Xarelto Litigation Enters New Phase, Prompting Court to Nix Joint Filings
The federal litigation involving thousands of Xarelto lawsuits is moving forward rapidly, prompting the Court to terminate the Joint Complaint filing procedures it established last year. According to a March 22nd Pretrial Order issued in the U.S. District Court, Eastern District of Louisiana, joint filings will no longer be permitted as of May 20, 2016.
More than 4,500 Xarelto bleeding claims have been filed in the Eastern District of Louisiana since the centralized litigation was created in December 2014. According to a recent report from Reuters, the proceeding still ranks among the fastest growing federal multidistrict litigations. All of the pending cases were filed on behalf of patients who allegedly experienced dangerous episodes of uncontrollable bleeding and related complications due to their use of the anticoagulant medication.
Last May, the Court issued an Order that allowed claims involving up to 100 plaintiffs to be filed in a single complaint. The joint filing procedures were intended to minimize the expenses of all parties, and to promote judicial efficiency. According to the Order issued last month, the Xarelto litigation is poised to enter a new phase. Thus, the Court has determined that is now appropriate to terminate the joint filing procedure.
Xarelto Lawsuits Being Prepped for Trial
Xarelto is a new-generation anticoagulant approved by the U.S. Food & Drug Administration (FDA) in 2011. Xarelto lawsuit plaintiffs claim that the drug’s manufacturers wrongly promoted the medication as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Among other things, they point out that internal bleeding associated with warfarin can be stopped via the administration of vitamin K. However, there is currently no approved antidote to reverse Xarelto bleeding.
Court records indicate that the federal Xarelto litigation will convene its first bellwether trials in February 2017. On March 7, 2016, the Court issued an Order identifying 40 Xarelto lawsuits selected for a bellwether discovery pool. These claims will undergo case-specific discovery, and eventually a number will be chosen for trial. Bellwether trials are an important component of most multidistrict litigations, as verdicts in such cases often provide insight into how juries might decide similar lawsuits.
Bernstein Liebhard LLP is representing a number of Xarelto plaintiffs, and our attorneys continue to provide free legal reviews to those who may have been harmed by this medication. To learn more, please call 877-779-1414.